Alluvi, previously BI 4744, presents a significant advance in obesity treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates impressive results in patient assessments, arguably exceeding https://alluvihealthcare880011.aioblogs.com/96082905/alluvi-a-detailed-examination-into-the-drug-s-potential